FGFR3 (V555M)
Sign in to save this workspaceFGFR3 · Variant type: point · HGVS: p.V555M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Brigatinib | 93.3% | 6.7% | 82.96 |
| 2 | Sunitinib | 84.1% | 15.9% | 91.73 |
| 3 | Defactinib | 82.8% | 17.2% | 92.68 |
| 4 | Pralsetinib | 81.0% | 18.9% | 93.43 |
| 5 | Fedratinib | 79.0% | 21.1% | 96.21 |
| 6 | Selpercatinib | 77.0% | 23.0% | 96.72 |
| 7 | Ponatinib | 76.2% | 23.8% | 78.23 |
| 8 | Futibatinib | 75.3% | 24.7% | 98.48 |
| 9 | Fostamatinib | 70.5% | 29.5% | 96.74 |
| 10 | Erdafitinib | 69.5% | 30.5% | 95.71 |
| 11 | Nintedanib | 66.5% | 33.5% | 90.23 |
| 12 | Entrectinib | 66.0% | 34.0% | 93.69 |
| 13 | Pacritinib | 65.7% | 34.3% | 88.64 |
| 14 | Axitinib | 61.3% | 38.7% | 93.23 |
| 15 | Infigratinib | 50.4% | 49.6% | 98.24 |
| 16 | Upadacitinib | 48.3% | 51.7% | 97.98 |
| 17 | Repotrectinib | 44.2% | 55.8% | 84.21 |
| 18 | Pemigatinib | 44.0% | 56.0% | 98.23 |
| 19 | Avapritinib | 41.6% | 58.4% | 97.73 |
| 20 | Crizotinib | 37.5% | 62.5% | 91.39 |
| 21 | Imatinib | 30.8% | 69.2% | 99.00 |
| 22 | Deucravacitinib | 28.5% | 71.5% | 98.99 |
| 23 | Alpelisib | 28.2% | 71.8% | 97.22 |
| 24 | Ibrutinib | 25.3% | 74.7% | 94.74 |
| 25 | Gilteritinib | 24.5% | 75.5% | 88.97 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Brigatinib | 93.3% | 74.6% | +18.7% |
| Sunitinib | 84.1% | 66.2% | +17.9% |
| Defactinib | 82.8% | 65.7% | +17.2% |
| Pralsetinib | 81.0% | 90.6% | -9.5% |
| Fedratinib | 79.0% | 67.1% | +11.9% |
| Selpercatinib | 77.0% | 86.6% | -9.6% |
| Ponatinib | 76.2% | 96.7% | -20.6% |
| Futibatinib | 75.3% | 99.0% | -23.7% |
| Fostamatinib | 70.5% | — | — |
| Erdafitinib | 69.5% | 99.1% | -29.5% |
| Nintedanib | 66.5% | 91.0% | -24.4% |
| Entrectinib | 66.0% | 73.3% | -7.4% |
| Pacritinib | 65.7% | 70.5% | -4.7% |
| Axitinib | 61.3% | 93.1% | -31.9% |
| Infigratinib | 50.4% | 98.6% | -48.2% |
| Upadacitinib | 48.3% | — | — |
| Repotrectinib | 44.2% | — | — |
| Pemigatinib | 44.0% | 99.4% | -55.3% |
| Avapritinib | 41.6% | — | — |
| Crizotinib | 37.5% | — | — |
| Imatinib | 30.8% | — | — |
| Deucravacitinib | 28.5% | 93.3% | -64.8% |
| Alpelisib | 28.2% | 98.6% | -70.4% |
| Ibrutinib | 25.3% | — | — |
| Gilteritinib | 24.5% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.4ms